Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [2] - The company's business model aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [2] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [2] Upcoming Investor Conferences - Ligand management will participate in the H.C. Wainwright Royalty Company Conference on May 13, 2025, at 3:30 p.m. ET, including a fireside chat and one-on-one meetings [4] - Management will also take part in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, at 2:05 p.m. ET, featuring a fireside chat and one-on-one meetings [4] - Additionally, Ligand will engage in one-on-one meetings at the Craig-Hallum Institutional Investor Conference on May 28, 2025 [4] Technology Platforms - Ligand operates two infrastructure-light royalty-generating technology platforms: Captisol® and NITRICIL™ [2] - The Captisol® platform is designed to optimize the solubility and stability of drugs through a chemically modified cyclodextrin structure [2] - The NITRICIL™ platform allows for tunable dosing, enabling adjustable drug release profiles for proprietary formulations targeting a broad range of indications [2] Investor Relations - The company utilizes its investor relations website and social media to disclose material non-public information and comply with disclosure obligations under Regulation FD [3] - Investors are encouraged to monitor the company's website and social media accounts for updates, press releases, SEC filings, and public conference calls [3]

Core Viewpoint - The proposed merger between Ligand Pharmaceuticals and Channel Therapeutics aims to enhance the commercialization of Pelthos' ZELSUVMI™, a novel FDA-approved drug for treating Molluscum contagiosum infections, with a capital raise of $50 million from strategic investors [2][4][6]. Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on enabling scientific advancement through financing and licensing technologies, aiming to create a diversified portfolio of revenue streams [14]. - Channel Therapeutics is a clinical-stage biotechnology company developing non-opioid therapeutics for pain management, with a focus on the NaV1.7 sodium ion-channel [12]. - Pelthos Therapeutics, a subsidiary of Ligand, is dedicated to commercializing innovative therapeutic products, including ZELSUVMI™ [10]. Product Details - ZELSUVMI™ (berdazimer) is a topical gel approved by the FDA in 2024 for the treatment of Molluscum contagiosum in patients aged one year and older, and is the first prescription therapy that can be applied at home [3][9]. - The product utilizes Pelthos' proprietary nitric oxide-based technology platform, NITRICIL™, and is designed to be easy to use for patients, parents, and caregivers [5][9]. Market Opportunity - Molluscum contagiosum is a common skin infection affecting an estimated 16.7 million people in the U.S., with a significant unmet medical need for effective home treatment options [4][5]. - The merger is expected to provide near-term revenue generation opportunities from ZELSUVMI™ and advance Channel's existing pain treatment programs [4][6]. Transaction Details - The merger agreement stipulates that Channel will acquire 100% of Pelthos' equity interests, with Ligand investing $18 million and the investor group contributing $32 million, totaling $50 million [6][7]. - The combined company will operate under the name Pelthos Therapeutics Inc. and will be listed on the NYSE American under the ticker PTHS [2][7]. Leadership Structure - Following the merger, Scott Plesha will serve as CEO of the combined company, while Frank Knuettel II will take on the role of CFO [7].

Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare- dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformatio ...

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference (Miami). Management will participate in one-on-one meetings on March 10, 2025. Barclays 27th Annual Global Healthcare Conference (Miami). Management will participate in a fireside chat on March 12, 2025 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transitio ...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis Todd Davis - CEO Paul Hadden - Senior Vice President of Investments and Business Development Tavo Espinoza - Chief Financial Officer Lauren Hay - Vice President of Strategic Planning and Investment Analytics Conference Call Participants Matt Hewitt - Craig-Hallum Joseph Pantginis - HC Wainwright Douglas Miehm ...

Ligand Pharmaceuticals (LGND) Q4 2024 Earnings Call February 27, 2025 08:30 AM ET Company Participants Melanie Herman - Executive Director - Investor Relations and FP&ATodd Davis - CEOPaul Hadden - Senior Vice President of Investments & Business DevelopmentTavo Espinoza - CFOLauren Hay - Vice President - Strategic Planning & Investment Analytics Conference Call Participants Matt Hewitt - Senior Research AnalystJoseph Pantginis - MD & Senior Healthcare AnalystDouglas Miehm - AnalystTrevor Allred - Biotech An ...

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.25 1 A reconciliation of forward-looking non-GAAP adjusted earnings per diluted share to the most directly comparable GAAP measure is not available without unreasonable effort, as certain items cannot be reasonably predicted because of thei ...

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.00-$6.25 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2024, and provided an operating forecast and business updat ...

Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has closed a royalty financing agreement with Castle Creek Biosciences, Inc. to support the Phase 3 clinical study of D- ...